A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.

An effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a c...

Full description

Bibliographic Details
Main Authors: Dilip Mahalanabis, Anna Lena Lopez, Dipika Sur, Jacqueline Deen, Byomkesh Manna, Suman Kanungo, Lorenz von Seidlein, Rodney Carbis, Seung Hyun Han, Seong Hye Shin, Stephen Attridge, Raman Rao, Jan Holmgren, John Clemens, Sujit K Bhattacharya
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-06-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2396289?pdf=render
_version_ 1818550554957185024
author Dilip Mahalanabis
Anna Lena Lopez
Dipika Sur
Jacqueline Deen
Byomkesh Manna
Suman Kanungo
Lorenz von Seidlein
Rodney Carbis
Seung Hyun Han
Seong Hye Shin
Stephen Attridge
Raman Rao
Jan Holmgren
John Clemens
Sujit K Bhattacharya
author_facet Dilip Mahalanabis
Anna Lena Lopez
Dipika Sur
Jacqueline Deen
Byomkesh Manna
Suman Kanungo
Lorenz von Seidlein
Rodney Carbis
Seung Hyun Han
Seong Hye Shin
Stephen Attridge
Raman Rao
Jan Holmgren
John Clemens
Sujit K Bhattacharya
author_sort Dilip Mahalanabis
collection DOAJ
description An effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India.Double-blind, randomized, placebo controlled trial.The trial was conducted in the clinical trial ward of the Infectious Diseases Hospital in Kolkata, India.The participants were 101 healthy adults (males and non-pregnant females) aged 18-40 years and 100 healthy children (males and non-pregnant females) aged 1-17 years.Participants were randomized to receive either the bivalent killed whole cell oral cholera vaccine or placebo (killed oral Escherichia coli K12).For safety: proportion of subjects with adverse events during the duration of study participation. For immunogenicity: Proportion of subjects who had a > or = 4-fold rise in serum vibriocidal antibody titers 14 days after the second dose of vaccine or placebo.Adverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups. Among adults 4% of vaccine and 8% of placebo recipients and among children 4% of vaccine and 2% of placebo recipients had at least one adverse event within 28 days of the first dose of the vaccine. Following immunization, 53% of adult and 80% of children vaccinees showed a > or = 4 fold rise in serum V. cholerae O1 vibriocidal antibody titers. A less pronounced response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees.We found the vaccine to be safe and immunogenic in a cholera-endemic area in India.ClinicalTrials.gov NCT00119197.
first_indexed 2024-12-12T08:48:01Z
format Article
id doaj.art-887a4631eb254cc0aeb244cfc7aa1fa4
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-12T08:48:01Z
publishDate 2008-06-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-887a4631eb254cc0aeb244cfc7aa1fa42022-12-22T00:30:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032008-06-0136e232310.1371/journal.pone.0002323A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.Dilip MahalanabisAnna Lena LopezDipika SurJacqueline DeenByomkesh MannaSuman KanungoLorenz von SeidleinRodney CarbisSeung Hyun HanSeong Hye ShinStephen AttridgeRaman RaoJan HolmgrenJohn ClemensSujit K BhattacharyaAn effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India.Double-blind, randomized, placebo controlled trial.The trial was conducted in the clinical trial ward of the Infectious Diseases Hospital in Kolkata, India.The participants were 101 healthy adults (males and non-pregnant females) aged 18-40 years and 100 healthy children (males and non-pregnant females) aged 1-17 years.Participants were randomized to receive either the bivalent killed whole cell oral cholera vaccine or placebo (killed oral Escherichia coli K12).For safety: proportion of subjects with adverse events during the duration of study participation. For immunogenicity: Proportion of subjects who had a > or = 4-fold rise in serum vibriocidal antibody titers 14 days after the second dose of vaccine or placebo.Adverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups. Among adults 4% of vaccine and 8% of placebo recipients and among children 4% of vaccine and 2% of placebo recipients had at least one adverse event within 28 days of the first dose of the vaccine. Following immunization, 53% of adult and 80% of children vaccinees showed a > or = 4 fold rise in serum V. cholerae O1 vibriocidal antibody titers. A less pronounced response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees.We found the vaccine to be safe and immunogenic in a cholera-endemic area in India.ClinicalTrials.gov NCT00119197.http://europepmc.org/articles/PMC2396289?pdf=render
spellingShingle Dilip Mahalanabis
Anna Lena Lopez
Dipika Sur
Jacqueline Deen
Byomkesh Manna
Suman Kanungo
Lorenz von Seidlein
Rodney Carbis
Seung Hyun Han
Seong Hye Shin
Stephen Attridge
Raman Rao
Jan Holmgren
John Clemens
Sujit K Bhattacharya
A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
PLoS ONE
title A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
title_full A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
title_fullStr A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
title_full_unstemmed A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
title_short A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
title_sort randomized placebo controlled trial of the bivalent killed whole cell oral cholera vaccine in adults and children in a cholera endemic area in kolkata india
url http://europepmc.org/articles/PMC2396289?pdf=render
work_keys_str_mv AT dilipmahalanabis arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT annalenalopez arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT dipikasur arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT jacquelinedeen arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT byomkeshmanna arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT sumankanungo arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT lorenzvonseidlein arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT rodneycarbis arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT seunghyunhan arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT seonghyeshin arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT stephenattridge arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT ramanrao arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT janholmgren arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT johnclemens arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT sujitkbhattacharya arandomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT dilipmahalanabis randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT annalenalopez randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT dipikasur randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT jacquelinedeen randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT byomkeshmanna randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT sumankanungo randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT lorenzvonseidlein randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT rodneycarbis randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT seunghyunhan randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT seonghyeshin randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT stephenattridge randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT ramanrao randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT janholmgren randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT johnclemens randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia
AT sujitkbhattacharya randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia